Clal Insurance Enterprises Holdings (XTAE:CLIS) Research & Development: ₪0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:CLIS Clal Insurance Enterprises Holdings Ltd XTAE:CLIS
69 GF Score
Price ₪242.80
GF Value ₪104.24
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Clal Insurance Enterprises Holdings Research & Development?

Clal Insurance Enterprises Holdings XTAE:CLIS +1.89% 69 Research & Development is ₪0 Mil as of Mar. 2026. GuruFocus rates XTAE:CLIS with a GF Score™ of 69/100 and a GF Value™ of ₪104.24 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Clal Insurance Enterprises Holdings's Research & Development for the three months ended in Mar. 2026 was ₪0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₪0 Mil.

Clal Insurance Enterprises Holdings  (XTAE:CLIS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Clal Insurance Enterprises Holdings Research & Development Related Terms

Clal Insurance Enterprises Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Clal Insurance Enterprises Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clal Insurance Enterprises Holdings Research & Development Chart

Clal Insurance Enterprises Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Clal Insurance Enterprises Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XTAE:CLIS
69GF Score
Clal Insurance Enterprises Holdings Ltd XTAE:CLIS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clal Insurance Enterprises Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₪0 Mil mean?
Clal Insurance Enterprises Holdings (XTAE:CLIS) has a Research & Development of ₪0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Clal Insurance Enterprises Holdings and its competitors.
Is Clal Insurance Enterprises Holdings' Research & Development too high?
Clal Insurance Enterprises Holdings' current Research & Development is ₪0 Mil. Overall, Clal Insurance Enterprises Holdings has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clal Insurance Enterprises Holdings' Research & Development compare to AFL and MET?
Clal Insurance Enterprises Holdings' Research & Development of ₪0 Mil can be compared against companies in the Insurance industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Insurance company?
A good Research & Development depends on the Insurance industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Clal Insurance Enterprises Holdings and its competitors. Clal Insurance Enterprises Holdings's current Research & Development is ₪0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clal Insurance Enterprises Holdings stock overvalued right now?
Based on GuruFocus' analysis, Clal Insurance Enterprises Holdings (XTAE:CLIS) is currently considered Significantly Overvalued. The stock's GF Value™ is ₪104.24, compared to a current price of ₪242.80 — trading 132.9% above its estimated fair value. The current Research & Development is ₪0 Mil. Clal Insurance Enterprises Holdings' overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Clal Insurance Enterprises Holdings (XTAE:CLIS), the current Research & Development is ₪0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clal Insurance Enterprises Holdings (XTAE:CLIS) Overvalued in 2026?

Based on GuruFocus' analysis, Clal Insurance Enterprises Holdings stock appears to be overvalued. The current stock price of ₪242.80 is trading 132.9% above its estimated GF Value™ of ₪104.24. GuruFocus considers Clal Insurance Enterprises Holdings to be Significantly Overvalued.

Key valuation signals for XTAE:CLIS:

  • Research & Development: ₪0 Mil
  • GF Value™: ₪104.24 vs. price of ₪242.80 (132.9% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the XTAE:CLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clal Insurance Enterprises Holdings Business Description

Address 36 Raul Wallenberg Road, Kiryat Atidim, Tower 8, Tel Aviv, ISR, 6136902
Clal Insurance Enterprises Holdings Ltd is an insurance company, part of IDB Group, a conglomerate from Israel. Its lines of business are Nonlife insurance, Health insurance, Pensions, and provident funds for private and corporate clients. Clal insurance divisions are nonlife insurance, long-term savings, and health. The nonlife insurance division offers automotive, property, personal accidents, guarantees, liability, and marine insurance, among others. The life insurance and long-term savings division manages long-term assets, such as life insurance, pensions, and funds. The health insurance division consists of health insurance products, such as local and overseas surgeries, transplants, medications, critical illness, long-term care, and accidents. The company's main market is Israel.
69GF Score

Get the complete analysis for XTAE:CLIS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪242.80
Price
₪104.24
GF Value